|
Home | Business News | Browse by Publication | M | M2 Presswire |
||
Trophos successfully completes phase 1 clinical trials for novel compound to treatment neurodegenerative diseases; Trials show good patient tolerance, achievement of predicted effective dose, and an excellent safety profile for TRO19622, one of a number of proprietary drug candidates being developed for the treatment of ALS (Lou Gehrig's disease), SMA and other neurological disorders, including neuropathic pain.
|
||
|
Article Excerpt |
||
|
View this article FREE - Now for a Limited Time, try Goliath Business News
|
||
|
||
